Last reviewed · How we verify
NCT05161845
Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live
Phase 4 trial testing Measles, Mumps and Rubella Combined Vaccine, Live in Immunotoxicity in 1,068 participants. Completed in 1 October 2022.
4 April 2022
Quick facts
| Lead sponsor | Shanghai Institute Of Biological Products |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 1,068 |
| Start date | 23 December 2021 |
| Primary completion | 4 April 2022 |
| Estimated completion | 1 October 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Measles, Mumps and Rubella Combined Vaccine, Live — full drug profile →
Conditions studied
- Immunotoxicity — all drugs for Immunotoxicity →
- Vaccine — all drugs for Vaccine →
Sponsor
Shanghai Institute Of Biological Products
Who can join
Adults 8 Months to 12 Months, any sex, with Immunotoxicity or Vaccine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the immunogenicity, lot-to-lot consistency and safety of three consecutive batches of Measles, Mumps and Rubella Combined Vaccine, Live.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05161845
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Immunotoxicity
Currently open trials in the same condition.
- NCT06627595 — Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management · recruiting
- NCT04119713 — Autoimmunity After Checkpoint Blockade · recruiting
Other Shanghai Institute Of Biological Products trials
Trials by the same sponsor.
- NCT07363837 — Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants · Phase 1, PHASE2 · not yet recruiting
- NCT07327398 — Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 2 · not yet recruiting
- NCT07253675 — Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo · Phase 2 · not yet recruiting
- NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
- NCT07205198 — A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects. · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05161845 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Institute Of Biological Products
- Last refreshed: 14 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05161845.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing